Stockscreener 앱 받기
22.91
3.01%
0.67
시간 외 거래:
22.91
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream - MSN
Fundamentals Check: Can Arcutis Biotherapeutics Inc stock outperform in a bear market2026 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - MSN
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Stock Holdings Lessened by Suvretta Capital Management LLC - MarketBeat
Stock Recap: Can Arcutis Biotherapeutics Inc sustain earnings growth2026 WrapUp & Expert-Curated Trade Recommendations - baoquankhu1.vn
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis reports long-term data on eczema cream for young children - Investing.com Canada
Arcutis reports long-term data on eczema cream for young children By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Reports Positive Findings from Zo - GuruFocus
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - The Manila Times
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - Bitget
Year-long eczema study: Arcutis cream eased symptoms in young kids - Stock Titan
ARQT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline - TipRanks
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - AOL.com
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating - Yahoo Finance
GW&K Investment Management LLC Sells 206,391 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth - Sahm
Arcutis Promotes Mas Matsuda to Executive Vice President, Chief Legal Officer - Contract Pharma
Mas Matsuda Promoted to Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics - geneonline.com
Arcutis Biotherapeutics (ARQT) Elevates Legal Leader to Executiv - GuruFocus
Arcutis Biotherapeutics Promotes Mas Matsuda to Executive Vice President and Chief Legal Officer - Quiver Quantitative
Lawyer behind six ZORYVE FDA wins takes top legal role at Arcutis - Stock Titan
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis Biotherapeutics Director Sells Shares - TradingView
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Masaru Matsuda Sells 3,325 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Masaru Matsuda Sells 8,733 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (ARQT) officer sells 3,687 shares and receives major equity grants - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Arcutis Biotherapeutics (ARQT) Begins Phase 1 Study of ARQ-234 - GuruFocus
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial - Investing.com
New Arcutis trial tests immune-checkpoint drug for atopic dermatitis - Stock Titan
Targets Report: Can Arcutis Biotherapeutics Inc deliver consistent EPS growth2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Masaru Matsuda reports Rule 144 share sales for Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) insider sale notice: 3,687 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 37,349 shares after vesting - Stock Titan
Mizuho cuts Arcutis stock price target to $35 on higher costs - Investing.com UK
Arcutis Biotherapeutics (ARQT) insider sale notice: 10,000 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.9% After Analyst Downgrade - MarketBeat
ARQT: Mizuho Lowers Price Target but Maintains Outperform Rating - GuruFocus
Mizuho Has Lowered Expectations for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):